Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+9.0%
Amgen logo
AmgenAMGN
$1.82B+5.1%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$121.03M-134%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$39.73M+11.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$49.66M-2.4%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
-$40.37M-5.8%

Segments

By geography

See full
US-$59.58M+11.3%
GB-$272K+96.0%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s net income?
Climb Bio, Inc. (CLYM) reported net income of -$13.72M in Q1 2026.
How has Climb Bio, Inc.'s net income changed year-over-year?
Climb Bio, Inc.'s net income increased by 34.0% year-over-year, from -$20.78M to -$13.72M.
What is the long-term trend for Climb Bio, Inc.'s net income?
Over 4 years (2021 to 2025), Climb Bio, Inc.'s net income has grown at a 6.0% compound annual growth rate (CAGR), from -$47.48M to -$59.85M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.